The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1686
October 2, 2023
View Complete Issue         Table of Contents 2019 
Valoctocogene Roxaparvovec (Roctavian) – A Gene Therapy for Severe Hemophilia A
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Valoctocogene Roxaparvovec (Roctavian) – A Gene Therapy for Severe Hemophilia A
October 2, 2023 (Issue: 1686)
Valoctocogene roxaparvovec-rvox (Roctavian – Biomarin), an adeno-associated virus (AAV) vector-based gene therapy, has been approved by the FDA for one-time treatment of severe hemophilia A in adults without pre-existing antibodies to...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Valoctocogene Roxaparvovec (Roctavian) – A Gene Therapy for Severe Hemophilia A
Article code: 1686c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.